Chance Pharmaceuticals 畅溪制药
A clinical-stage biotech company focusing on discovering, developing and commercializing inhalation therapies.
A clinical-stage biotech company focusing on discovering, developing and commercializing inhalation therapies.
Chance Pharmaceuticals 畅溪制药 is a clinical-stage biotech company with a focus on discovering, developing, and commercializing inhalation therapies. Founded in 2015 in China, the company is dedicated to bringing transformative inhalation therapies to market for the treatment of debilitating diseases. The team, comprised of passionate and experienced experts in inhalation therapy, is committed to leveraging the potential of inhalation therapy to improve and transform the lives of individuals affected by diseases with unmet treatment needs. Recently, the company received a Series C investment from Fortune Venture Capital on 04 January 2022. With its vision, expertise, and recent investment, Chance Pharmaceuticals is poised to make a significant impact on the biotechnology, healthcare, and pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | Unknown | 1 |
|
04 Jan 2022 |
| Series C | $30.00M | 4 |
|
11 Oct 2021 |
| Series B | CNY80.00M | 1 | Yipinhong Pharmacy | 16 Jun 2020 |
| Series A | CNY55.00M | 3 |
|
01 Jan 2018 |
| Angel Round | CNY10.00M | 1 |
|
01 Apr 2016 |
No recent news or press coverage available for Chance Pharmaceuticals 畅溪制药.
We care about your data, and we'd love to use cookies make your experience better.
